FDA Removes Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-alone…
Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on…
Read More...
Read More...
